Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Natalie L StennisMichelle Macaraig

Abstract

Completion of treatment for tuberculosis infection (TBI) with 9 months of self-administered daily isoniazid (9H) has historically been low (<50%) among New York City (NYC) Health Department tuberculosis clinic patients. Treatment of TBI with 3 months of once-weekly isoniazid and rifapentine (3HP) administered under directly observed therapy (DOT) might increase treatment acceptance and completion. The study population included patients diagnosed with TBI at 2 NYC Health Department tuberculosis clinics from January 2013 through November 2013. Treatment acceptance and completion with 3HP were compared with historical estimates. Treatment outcomes, side effects, and reasons for refusing 3HP were described. Among 631 patients eligible for TBI treatment, 503 (80%) were offered 3HP; 302 (60%) accepted, 92 (18%) chose other treatment, and 109 (22%) refused treatment. The most common reason for refusing 3HP was the clinic-based DOT requirement. Forty (13%) patients treated with 3HP experienced side effects--9 were restarted on 3HP, 18 switched treatment regimens, and 13 discontinued. Although treatment acceptance did not differ from historical estimates (78% vs 79%, P = .75), treatment completion increased significantly (65% vs 34%, P ...Continue Reading

References

Apr 28, 1994·The New England Journal of Medicine·S E WeisB H Foresman
Feb 25, 1993·The New England Journal of Medicine·G J Annas
May 15, 2003·American Journal of Respiratory and Critical Care Medicine·Philip A LoBue, Kathleen S Moser
Aug 7, 2009·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Jiehui LiMarie Dorsinville
Dec 14, 2011·The New England Journal of Medicine·Timothy R SterlingUNKNOWN TB Trials Consortium PREVENT TB Study Team
Mar 15, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·P W ColsonUNKNOWN Tuberculosis Epidemiologic Studies Consortium
Nov 10, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·D ShepardsonW R Mac Kenzie

❮ Previous
Next ❯

Citations

Jan 13, 2017·Critical Reviews in Analytical Chemistry·Guilherme Felipe Dos Santos FernandesJean Leandro Dos Santos
Mar 25, 2018·Pharmacoepidemiology and Drug Safety·Christopher PeaseGonzalo G Alvarez
Mar 2, 2017·Canada Communicable Disease Report = Relevé Des Maladies Transmissibles Au Canada·C PeaseG G Alvarez
Oct 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Esther Arguello PerezArthur E Brown

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.

Related Papers

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
D ShepardsonW R Mac Kenzie
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
N SalomonS R Yancovitz
American Journal of Respiratory and Critical Care Medicine
Denis Anthony Mitchison
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
H DavidsonF N Laufer
© 2021 Meta ULC. All rights reserved